fashion -WSS

fashion

author：Wikipedia 2025-10-01 14:20:19 - browse：2

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： JPM pitch from hospitals? Revenue streams outside of patient care

knowledge

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

Pregnant women don't need prenatal multivitamins, study concludes

Profiling embryos to choose those with higher IQs is almost a reality

Fetal cell organoids grown from amniotic fluid, study finds

The untold story of TV’s first prescription drug ad

Merck to acquire Harpoon Therapeutics for $680 million

hotspot

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Physician assistants need a new name. Here's what it should be

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

First over

As demand for Covid shots wanes, Moderna seeks its next success

JPM pitch from hospitals? Revenue streams outside of patient care

23andMe had bad news about my health. I wish a person had delivered it

Ascension's ugly legal battle over care for poor patients in Texas

Hepatitis C has a cure — but many Americans still lack access to it

Longer MASH drug regimen improved liver, Akero study finds

hotspot

The untold story of TV’s first prescription drug ad

Physician assistants need a new name. Here's what it should be

Harvard's David Sinclair gets blowback over aging

Lack of health data on LGBTQ+ people has serious consequences

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

knowledge

entertainment

focus